Lakefront Biotherapeutics (LKFT) EBIT (2014 - 2026)
Lakefront Biotherapeutics (LKFT) reported EBIT of -$74.6 million for Q1 2026, up 55.33% year-over-year from -$48.0 million in Q1 2025, and down 108.46% quarter-over-quarter from $881.4 million in Q4 2025.
Lakefront Biotherapeutics (LKFT) EBIT (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has 13 years of EBIT data on file, last reported at -$74.6 million in Q1 2026.
- EBIT for Q1 2026 came in at -$74.6 million, up 55.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $446.3 million (up 329.45% YoY), and the FY2025 annual result was $343.4 million, up 270.65% from the prior year.
- EBIT fell to -$74.6 million in Q1 2026 per LKFT's latest filing, from $881.4 million in the prior quarter.
- Over five years, EBIT peaked at $881.4 million in Q4 2025 and troughed at -$538.5 million in Q3 2025.
- A 5-year average of $21.7 million and a median of -$15.4 million in 2023 frame the typical range for EBIT.
- The sharpest annual moves came in 2023 and 2024: EBIT jumped 5629.05% in 2023, then slumped 1276.11% in 2024.
- A 5-year view of EBIT shows it stood at $4.1 million in 2022, then jumped by 5629.05% to $233.8 million in 2023, then sank by 67.41% to $76.2 million in 2024, then jumped by 1056.85% to $881.4 million in 2025, then plunged by 108.46% to -$74.6 million in 2026.
- Business Quant data shows LKFT's EBIT at -$74.6 million in Q1 2026, $881.4 million in Q4 2025, and -$538.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -65.83 Mn |
| 10 | Lakefront Biotherapeutics | 9.64 Bn | 9.64 Bn | 1.97 Mn | -74.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.58 Mn |
| Dec 31, 2025 | 881.41 Mn |
| Sep 30, 2025 | -538.49 Mn |
| Jun 30, 2025 | 177.91 Mn |
| Mar 31, 2025 | -166.94 Mn |
| Dec 31, 2024 | 76.19 Mn |
| Sep 30, 2024 | -212.96 Mn |
| Jun 30, 2024 | 109.22 Mn |
| Mar 31, 2024 | -35.99 Mn |
| Dec 31, 2023 | 233.80 Mn |
| Sep 30, 2023 | -15.48 Mn |
| Jun 30, 2023 | -14.70 Mn |
| Mar 31, 2023 | -15.24 Mn |
| Dec 31, 2022 | 4.08 Mn |
| Sep 30, 2022 | -37.87 Mn |
| Mar 31, 2022 | -23.73 Mn |
| Dec 31, 2021 | 4.73 Mn |
| Jun 30, 2021 | -56.30 Mn |
| Mar 31, 2021 | -61.27 Mn |
| Dec 31, 2020 | -212.94 Mn |